Pharvaris N.V. (NASDAQ:PHVS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Pharvaris N.V. (NASDAQ:PHVS) have received an average recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $41.70.

Several equities analysts have weighed in on PHVS shares. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Royal Bank Of Canada started coverage on shares of Pharvaris in a research note on Monday. They issued an “outperform” rating and a $52.00 price objective for the company. Morgan Stanley lifted their target price on shares of Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a research note on Thursday, December 4th. Wall Street Zen downgraded shares of Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Finally, Guggenheim increased their price target on Pharvaris from $32.00 to $39.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th.

Institutional Trading of Pharvaris

Several institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in Pharvaris by 41.1% during the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after purchasing an additional 15,769 shares during the period. JPMorgan Chase & Co. boosted its stake in Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after purchasing an additional 783 shares during the period. Legal & General Group Plc grew its holdings in Pharvaris by 17.2% during the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock valued at $203,000 after buying an additional 1,695 shares in the last quarter. Amundi grew its holdings in Pharvaris by 2,741,600.0% during the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock valued at $489,000 after buying an additional 27,416 shares in the last quarter. Finally, HighVista Strategies LLC raised its position in shares of Pharvaris by 4.3% during the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock valued at $418,000 after buying an additional 971 shares during the last quarter.

Pharvaris Trading Down 3.8%

Shares of NASDAQ:PHVS opened at $26.38 on Friday. The stock has a 50 day moving average of $26.71 and a 200 day moving average of $24.96. Pharvaris has a 12-month low of $11.51 and a 12-month high of $29.80.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.